International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia
This contemporary, international, evidence-informed guidance aims to achieve the greatest
good for the greatest number of people with familial hypercholesterolaemia (FH) across …
good for the greatest number of people with familial hypercholesterolaemia (FH) across …
[HTML][HTML] World heart federation cholesterol roadmap 2022
Background: Atherosclerotic cardiovascular diseases (ASCVD) including myocardial
infarction, stroke and peripheral arterial disease continue to be major causes of premature …
infarction, stroke and peripheral arterial disease continue to be major causes of premature …
Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models
RG Lee, AM Mazzola, MC Braun, C Platt, SB Vafai… - Circulation, 2023 - Am Heart Assoc
Background: VERVE-101 is an investigational in vivo CRISPR base-editing medicine
designed to alter a single DNA base in the PCSK9 gene, permanently turn off hepatic …
designed to alter a single DNA base in the PCSK9 gene, permanently turn off hepatic …
[HTML][HTML] PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021
Moreover, over the last few years the approach to treatment of patients with a high
cardiovascular risk has totally changed from treatment aimed at a specific risk factor (ie …
cardiovascular risk has totally changed from treatment aimed at a specific risk factor (ie …
Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society
JE Roeters van Lennep, LS Tokgözoğlu… - European heart …, 2023 - academic.oup.com
Cardiovascular disease is the leading cause of death in women and men globally, with most
due to atherosclerotic cardiovascular disease (ASCVD). Despite progress during the last 30 …
due to atherosclerotic cardiovascular disease (ASCVD). Despite progress during the last 30 …
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease
J Brandts, KK Ray - Nature Reviews Cardiology, 2023 - nature.com
Lowering the levels of LDL cholesterol in the plasma has been shown to reduce the risk of
atherosclerotic cardiovascular disease (ASCVD). Several other lipoproteins, such as …
atherosclerotic cardiovascular disease (ASCVD). Several other lipoproteins, such as …
Screening in children for familial hypercholesterolaemia: start now
Screening in children for familial hypercholesterolaemia: start now Page 1 Screening in children
for familial hypercholesterolaemia: start now Urh Groselj 1 , Albert Wiegman 2 , and Samuel S …
for familial hypercholesterolaemia: start now Urh Groselj 1 , Albert Wiegman 2 , and Samuel S …
Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations
Familial hypercholesterolaemia (FH) is under-recognized and under-treated in Europe
leading to significantly higher risk for premature heart disease in those affected. As treatment …
leading to significantly higher risk for premature heart disease in those affected. As treatment …
Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome
Bempedoic acid is a new cholesterol-lowering drug, which has recently received US FDA
and EMA approval. This drug targets lipid and glucose metabolism as well as inflammation …
and EMA approval. This drug targets lipid and glucose metabolism as well as inflammation …
Inclisiran: how widely and when should we use it?
Abstract Purpose of Review Plasma levels of LDL cholesterol (LDL-C) are causally
associated with cardiovascular risk. Reducing LDL-C results in a decreased incidence of …
associated with cardiovascular risk. Reducing LDL-C results in a decreased incidence of …